H.C. Wainwright lowered the firm’s price target on Aprea Therapeutics (APRE) to $5 from $20 and keeps a Buy rating on the shares after Aprea provided an update on its pipeline progress and corporate outlook for 2026. The company will be shifting focus from its monotherapy study of ATRN-119 to focus on potential combination strategies, notes the analyst, who is adjusting focus to APR-1051, which now provides 100% of the valuation contribution to the firm’s model. APR-1051 is currently being evaluated in the ongoing Phase 1 ACESOT-1051 dose-escalation trial and near term catalysts include updated safety and efficacy data due in Q1 and completion of dose escalation expected in 2026, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics CEO issues letter to shareholders
- Aprea Therapeutics Secures $3.1M in Private Placement
- Aprea Therapeutics prices 2.62M shares at $1.165 in private placement
- Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating
- Aprea Therapeutics Reports Ongoing Financial Challenges